Detail akcie Cerus Corp online

Business Summary: Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Cerus Corp revenues increased 8% to $201.3M. Net loss decreased 44% to $20.9M. Revenues reflect United States segment increase of 7% to $132.1M, Other Countries segment increase of 11% to $49.5M, France segment increase of 7% to $19.7M. Lower net loss reflects Blood Safety segment loss decrease of 53% to $14.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.21 to -$0.11.